Image of red blood cells and abnormal white blood cells in an acute lymphocytic leukemia cell blood smear, analyzed by microscope at 1000x magnification. T Cell Acute Lymphoblastic Leukemia (T-ALL) ...
Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
Chimeric antigen receptor T (CAR-T) cell therapy has significantly transformed the management of cancer, specifically in patients suffering from leukemia and lymphoma. This treatment approach entails ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
Astellas Pharma Inc. and Vir Biotechnology Inc. have entered into a global strategic collaboration to advance VIR-5500.
WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies, a private company developing 1 st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners (MOLN) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage ...
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results